Variations in the gene that encodes for the vitamin D receptor were associated with the risk of developing Parkinson’s disease — and with side effects from common dopamine-related treatments, a Slovenian study showed. These findings may help identify people at risk of Parkinson’s as well as those at…
A collaborative effort between researchers in Spain and Norway is helping to enrich an understanding of the regulatory mechanisms behind the production of dopamine, the brain chemical messenger progressively lost in people with Parkinson’s disease. Specifically, the team determined the structure of tyrosine hydroxylase (TH) — the rate-limiting enzyme…
People who develop Parkinson’s disease before the age of 50 may have been born with the defective brain cells responsible for causing the illness, a study suggests. These results also reveal that a medicine, which is already approved by the U.S. Food and Drug Administration (FDA) for treating…
Treatment with PF-360, an investigational leucine-rich repeat kinase 2 (LRRK2) inhibitor, can efficiently decrease LRRK2’s phosphorylation levels, known to be elevated in Parkinson’s patients, in the brains of a mouse model of Parkinson’s disease, a preclinical study reports. However, despite some observed dose-dependent therapeutic effects, including gait improvement, no robust changes…
A modified form of a protein called Nurr1 that is able to protect against nerve cell death and restore dopamine production in a preclinical setting may pave the way for a possible new Parkinson’s therapy, a study reports. The study, “Lethal Factor Domain-Mediated Delivery of Nurr1 Transcription…
Get regular updates to your inbox.
